Venous Thromboembolism Risk among Transgender and Gender Nonbinary Individuals Receiving GenderAffirming Hormone Therapy

A majority of transgender and gender nonbinary (TGNB) individuals initiate hormone therapy (HT) with the goal of inducing physical changes to align with their appearance and gender identity. Several studies have found an increased risk of venous thromboembolism (VTE) among TGNB individuals on gender-aff9rming HT, especially among those receiving estrogen therapy. This study examined VTE prevalence and risk among TGNB patients on gender-aff9rming HT, who receive care from a center that specializes in TGNB care.